



# Omics approaches reveal clues for mitochondrial disease diagnosis and pathogenesis

Anu Suomalainen Wartiovaara  
FinMIT  
Biomedicum-Helsinki  
Molecular Neurology Research Program  
[Research.med.helsinki.fi/neuro](http://Research.med.helsinki.fi/neuro)


[anu.wartiovaara@helsinki.fi](mailto:anu.wartiovaara@helsinki.fi)





# 50 years of mitochondrial medicine




# Mitochondrial functions




# Respiratory chain



# Genetic defect of mitochondrial disease can lie in mitochondrial or nuclear DNA



Nuclear genes encode 1500 proteins targeted to mitochondria



mtDNA: encodes 13 proteins

# Mitochondrial disorders

Can occur in any tissue, with any symptoms, with any inheritance model





# Open questions in mitochondrial diseases



- Why so many different phenotypes?
- Why variable tissue specificity?
- What are the physiological responses to various mitochondrial defects?
- Can any of the processes be affected → treatment

# Novel tools for diagnosis





# Case report: Infantile hypertrophic cardiomyopathy

## Clinical

First child of healthy parents  
Normal pregnancy, neonatal period


4 months:

hypertrophic cardiomyopathy, muscle weakness  
lactate levels 2-7mmol/l



Brain MRI normal, EEG slightly slow


Rapidly progressive disease

10 months: death due to cardiac arrest



# Respiratory chain CI, CIII and CIV deficiency in heart





## **Whole-exome sequencing**

**Sequence of all coding gene regions of patient's genome**


→ 50-60 million short sequence fragments (FIMM)

→ 1.5% of the whole genome = exome (18,000 genes)

**Comparison to control genome:**

-Known variants vs mutations

# Enrichment of sequences to exons




Henna Tynismaa  
Pekka Ellonen  
Henrikki Almusa

## Results of whole-exome sequencing in the patient

P2	
All variants	65849
Unknown	6323
Map to gene	1549
Homozygous	43
Damaging	7
Mitochondrial	1

# Homozygous missense mutation Arg592Trp in the AARS2 gene (putative mitochondrial alanyl-tRNA synthetase)



# True disease causing mutation?


Presence in population

Absent in 400 control chromosomes


Presence in other CMP families

Functional consequences

# Family 2: prenatal hypertrophic cardiomyopathy




- Prenatal: extrasystolia
- At birth: poor condition, cardiomyopathy, hyperlactacidemia, death at postnatal day 3
- Brother died in utero at week 40
- Compound heterozygosity for two AARS2 mutations





## Patient 2 has a homozygous missense mutation R592W in the AARS2 gene (putative mitochondrial alanyl-tRNA synthetase) - shared by another patient




# Aminoacyl-tRNA synthetases

Charges a tRNA with amino acid

Specific synthetases for each tRNA-aa pair; mitochondrial and cytoplasmic

tRNA structure specific; recognition often based on anticodon; amino acid specificity lower




## Special features of Ala-tRNA synthetases?

No selectivity between Ala, Ser and Gly in the active site

Removal of incorrect amino acid in the editing domain


No anticodon binding domain

Enzyme specifically recognizes conserved G:U base pair in the tRNA acceptor stem



Liliya Euro



# Multiple sequence analysis: human AARS2 structure utilizing known bacterial AlaRS structures as template




*E.coli* AlaRS  
36.6 % identity  
52.6 % similarity

*Pyrococcus horikoshii* AlaRS  
30.1 % identity  
42.7 % similarity

# L155R affects architecture of the catalytic domain R592W predicted to affect tRNA binding at editing domain



Amino acyl formation  
affected at catalytic  
site



**L155R**

Amino acylation defect



Reduced alanine  
incorporation to  
polypeptides

**R592W**

Editing defect





Misincorporation of amino  
acids (serine, glycine) into  
polypeptides



impaired  
mitochondrial protein  
synthesis

# Minor effect in myotube mitochondrial translation

But recovery from translation challenge slow






# Tissue specificity?

## Can variable levels of amino acids explain cardiac manifestation?

Metabolomic analysis: comprehensive two-dimensional gas chromatography combined with time-of-flight mass spectrometry (Matej Oresic, VTT, Finland)



Alanine increased,  
no major changes in serine / glycine



## Mitochondrial aminoacyl-tRNA synthetase mutations are a common cause of inherited disease

DARS2	leucoencephalopathy, lactacidosis, brain stem & spinal cord involvement	2007
RARS2	Infantile encephalopathy, cerebellar degeneration	2010
YARS2	myopathy, lactic acidosis and sideroblastic anemia	2010
AARS2	Cardiomyopathy & myopathy	2011
HARS2	Ovarian dysgenesis & hearing loss	2011
SARS2	hyperuricaemia, pulmonary hypertension, infantile renal failure	2011

# Conclusions

Mitochondrial dysfunction: an important cause of childhood / infantile cardiomyopathy – hypertrophic & dilated

Mitochondrial translation defects may manifest primarily as early cardiomyopathy

Aminoacyl-tRNA synthetase mutations: an important cause of mitochondrial disease, with wide clinical variability – including CMPs

Exome analysis reveals new syndromes with variable clinical manifestations – not previously recognized as single-gene disorders

Singleton findings without obvious cell phenotype – subtle phenotype may be found if the pathway challenged

Gene search possible from a single patient  
Major progress in DNA diagnosis & research



Confirms diagnosis & inheritance pattern  
Provides means for genetic counseling & research of pathogenic mechanism

# Thank you



## Biomedicum-Helsinki, FinMIT

Henna Tynismaa  
Riikka Hämäläinen

Alexandra Götz  
Sofia Ahola-Erkkilä

Liliya Euro  
Pirjo Isohanni    Jenni Elo



## Collaborators

Tiina Tyni  
Taneli Raivio  
Riitta Karikoski

Tiina Ojala  
Johanna Tommiska  
Anders Paetau

HUCH & Helsinki University

Matej Oresic  
Pekka Ellonen, Henrikki Almusa

Tuulia Hyötyläinen

VTT  
FIMM sequencing unit

Kalle Simola, Outi Tammela

Tampere Univ, Central Hospital

